Robert Lutz - Strongbridge Biopharma Chief Bus. Officer
Executive
Mr. Robert Lutz is Chief Business Officer of the company. since October 2014. Prior to joining Strongbridge, he worked as a fulltime consultant at Medgenics, a publicly traded, earlystage, genetherapy and rare disease biotech company, from May 2014 to September 2014. Mr. Lutz worked at Shire Pharmaceuticals, a publicly traded specialty biopharmaceutical company, from November 2012 to April 2014, where he most recently served as Vice President and held key leadership positions in the Neurosciences Business unit. Prior to Shire Pharmaceuticals, Mr. Lutz worked in a variety of roles, including Vice President and Senior Associate, for Cinergy Corporationration, an electric and gas utility company since 2014.
| Age | 46 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 610 254 9200 |
| Web | http://www.strongbridgebio.com |
Strongbridge Biopharma Management Efficiency
The company has return on total asset (ROA) of (27.5) % which means that it has lost $27.5 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (87.06) %, meaning that it created substantial loss on money invested by shareholders. Strongbridge Biopharma's management efficiency ratios could be used to measure how well Strongbridge Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 18.68 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Strongbridge Biopharma has a current ratio of 2.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Strongbridge Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Strongbridge Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Strongbridge Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Strongbridge to invest in growth at high rates of return. When we think about Strongbridge Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Paul Thompson | Perseus Mining Limited | 54 | |
| Ty Vukelich | Employers Holdings | N/A | |
| Gili Brudno | Playtika Holding Corp | 50 | |
| Adam Johnson | National CineMedia | N/A | |
| Martijn Bosboom | Perseus Mining Limited | N/A | |
| Jerry Canning | National CineMedia | N/A | |
| Daniel Hahn | National CineMedia | N/A | |
| Amy Tunick | National CineMedia | N/A | |
| Darlan Monterisi | Playtika Holding Corp | N/A | |
| Douglas Jones | Perseus Mining Limited | N/A | |
| Scott Tanner | Cedar Fair LP | N/A | |
| Christopher Woodall | Perseus Mining Limited | N/A | |
| Barry Smith | Emerson Radio | N/A | |
| Monica Sauls | Cedar Fair LP | N/A | |
| Ted Watson | National CineMedia | N/A | |
| Brad Filbey | National CineMedia | N/A | |
| Ann Smith | Employers Holdings | N/A | |
| Lindsey Rynard | Employers Holdings | N/A | |
| Michael Russell | Cedar Fair LP | N/A | |
| Christina Ozuna | Employers Holdings | N/A | |
| Lindsay Greenfield | The Hanover Insurance | N/A | |
Management Performance
| Return On Equity | -87.06 | |||
| Return On Asset | -27.5 |
Strongbridge Biopharma Leadership Team
Elected by the shareholders, the Strongbridge Biopharma's board of directors comprises two types of representatives: Strongbridge Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Strongbridge. The board's role is to monitor Strongbridge Biopharma's management team and ensure that shareholders' interests are well served. Strongbridge Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Strongbridge Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Pauls, CEO and President and Director | ||
| Brian Davis, CFO | ||
| Richard Kollender, Director | ||
| Davis, CFO | ||
| Robert Lutz, Chief Bus. Officer | ||
| Garheng Kong, Director | ||
| John Johnson, Chairman of the Board | ||
| Marten Steen, Director | ||
| Stephen Long, Chief Legal Officer | ||
| Ruth MD, Chief Medical Officer | ||
| Ruth ThieroffEkerdt, Chief Medical Officer | ||
| Marcy Nanus, Vice President - Corporate Affairs | ||
| Hilde Steineger, Director | ||
| Per MD, Founder and Sr. Clinical Advisor | ||
| Scott Wilhoit, Chief Commercial Officer |
Strongbridge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Strongbridge Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -87.06 | |||
| Return On Asset | -27.5 | |||
| Profit Margin | (115.67) % | |||
| Operating Margin | (123.23) % | |||
| Current Valuation | 85.82 M | |||
| Shares Outstanding | 67.77 M | |||
| Shares Owned By Insiders | 13.64 % | |||
| Shares Owned By Institutions | 67.14 % | |||
| Number Of Shares Shorted | 570.8 K | |||
| Price To Earning | 5.54 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Strongbridge Biopharma information on this page should be used as a complementary analysis to other Strongbridge Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Strongbridge Stock
If you are still planning to invest in Strongbridge Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Strongbridge Biopharma's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |